Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016

Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016
Published Jun 08, 2016
177 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016, provides an overview of the Herpes Simplex Virus (HSV) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Simplex Virus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Simplex Virus (HSV) Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Virus (HSV) Infections
- The report reviews pipeline therapeutics for Herpes Simplex Virus (HSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Herpes Simplex Virus (HSV) Infections therapeutics and enlists all their major and minor projects
- The report assesses Herpes Simplex Virus (HSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Herpes Simplex Virus (HSV) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Virus (HSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identi

  
Source:
Document ID
GMDHC8166IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Herpes Simplex Virus (HSV) Infections Overview131
Therapeutics Development142
  Pipeline Products for Herpes Simplex Virus (HSV) Infections Overview141
  Pipeline Products for Herpes Simplex Virus (HSV) Infections Comparative Analysis151
Herpes Simplex Virus (HSV) Infections Therapeutics under Development by Companies163
Herpes Simplex Virus (HSV) Infections Therapeutics under Investigation by Universities/Institutes191
Herpes Simplex Virus (HSV) Infections Pipeline Products Glance203
  Late Stage Products201
  Clinical Stage Products211
  Early Stage Products221
Herpes Simplex Virus (HSV) Infections Products under Development by Companies233
Herpes Simplex Virus (HSV) Infections Products under Investigation by Universities/Institutes261
Herpes Simplex Virus (HSV) Infections Companies Involved in Therapeutics Development2740
  Adamis Pharmaceuticals Corporation271
  Admedus Ltd281
  AiCuris GmbH &Co. KG291
  Almirall, S.A.301
  Astellas Pharma Inc.311
  Beech Tree Labs, Inc.321
  Beijing Minhai Biotechnology Co., Ltd331
  BioApex, s.r.o.341
  CEL-SCI Corporation351
  Editas Medicine, Inc.361
  Epiphany Biosciences, Inc.371
  Foamix Pharmaceuticals Ltd.381
  Genocea Biosciences, Inc.391
  GenVec, Inc.401
  Immune Design Corp.411
  Immunovaccine, Inc.421
  JN-International Medical Corporation431
  Microbiotix, Inc.441
  Mymetics Corporation451
  NanoBio Corporation461
  NanoViricides, Inc.471
  Onxeo SA481
  PaxVax, Inc.491
  Profectus BioSciences, Inc.501
  ReceptoPharm, Inc.511
  Redbiotec AG521
  Sanofi531
  Sanofi Pasteur SA541
  Savoy Pharmaceuticals, Inc.551
  Shulov Innovative Science Ltd.561
  Spider Biotech571
  Starpharma Holdings Limited581
  TGV-Laboratories591
  Tomegavax, Inc.601
  United BioPharma, Inc.611
  Vaccibody AS621
  Vaxart, Inc.631
  Vical Incorporated641
  Vironova AB651
  ViroStatics srl661
Herpes Simplex Virus (HSV) Infections Therapeutics Assessment6710
  Assessment by Monotherapy Products671
  Assessment by Combination Products681
  Assessment by Target692
  Assessment by Mechanism of Action712
  Assessment by Route of Administration732
  Assessment by Molecule Type752
Drug Profiles7769
  (carrageenan + MIV-150 + zinc acetate) - Drug Profile771
    Product Description771
    Mechanism of Action771
    R&D Progress772
  acyclovir - Drug Profile791
    Product Description791
    Mechanism of Action791
    R&D Progress791
  acyclovir - Drug Profile801
    Product Description801
    Mechanism of Action801
    R&D Progress801
  amenamevir - Drug Profile811
    Product Description811
    Mechanism of Action811
    R&D Progress811
  Aspidasept - Drug Profile821
    Product Description821
    Mechanism of Action821
    R&D Progress821
  astodrimer - Drug Profile831
    Product Description831
    Mechanism of Action831
    R&D Progress832
  B-220 - Drug Profile851
    Product Description851
    Mechanism of Action851
    R&D Progress851
  BA-368 - Drug Profile861
    Product Description861
    Mechanism of Action861
    R&D Progress861
  BTL-TMLHSV - Drug Profile871
    Product Description871
    Mechanism of Action871
    R&D Progress871
  C-31G - Drug Profile881
    Product Description881
    Mechanism of Action881
    R&D Progress882
  CEL-1000 - Drug Profile901
    Product Description901
    Mechanism of Action901
    R&D Progress902
  EBT-104 - Drug Profile921
    Product Description921
    Mechanism of Action921
    R&D Progress921
  FIT-039 - Drug Profile931
    Product Description931
    Mechanism of Action931
    R&D Progress931
  G-103 - Drug Profile941
    Product Description941
    Mechanism of Action941
    R&D Progress941
  GEN-002 - Drug Profile951
    Product Description951
    Mechanism of Action951
    R&D Progress951
  GEN-003 - Drug Profile961
    Product Description961
    Mechanism of Action961
    R&D Progress962
  Gene Therapy for HSV-1 Eye Infections - Drug Profile981
    Product Description981
    Mechanism of Action981
    R&D Progress981
  genital herpes (virus like particle) vaccine - Drug Profile991
    Product Description991
    Mechanism of Action991
    R&D Progress991
  genital herpes vaccine - Drug Profile1001
    Product Description1001
    Mechanism of Action1001
    R&D Progress1001
  genital herpes vaccine - Drug Profile1011
    Product Description1011
    Mechanism of Action1011
    R&D Progress1011
  genital herpes vaccine - Drug Profile1021
    Product Description1021
    Mechanism of Action1021
    R&D Progress1021
  genital herpes vaccine - Drug Profile1031
    Product Description1031
    Mechanism of Action1031
    R&D Progress1031
  GV-2207 - Drug Profile1041
    Product Description1041
    Mechanism of Action1041
    R&D Progress1041
  herpes simplex virus [type 1, 2] vaccine - Drug Profile1051
    Product Description1051
    Mechanism of Action1051
    R&D Progress1051
  herpes simplex virus [type 1, 2] vaccine - Drug Profile1061
    Product Description1061
    Mechanism of Action1061
    R&D Progress1061
  herpes simplex virus 1 vaccine - Drug Profile1071
    Product Description1071
    Mechanism of Action1071
    R&D Progress1071
  herpes simplex virus 2 vaccine - Drug Profile1081
    Product Description1081
    Mechanism of Action1081
    R&D Progress1081
  herpes simplex virus 2 vaccine - Drug Profile1091
    Product Description1091
    Mechanism of Action1091
    R&D Progress1091
  herpes simplex virus 2 vaccine - Drug Profile1101
    Product Description1101
    Mechanism of Action1101
    R&D Progress1101
  herpes simplex virus 2 vaccine - Drug Profile1111
    Product Description1111
    Mechanism of Action1111
    R&D Progress1111
  herpes simplex virus 2 vaccine - Drug Profile1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1121
  herpes simplex virus 2 vaccine - Drug Profile1131
    Product Description1131
    Mechanism of Action1131
    R&D Progress1131
  herpes simplex virus 2 vaccine - Drug Profile1141
    Product Description1141
    Mechanism of Action1141
    R&D Progress1141
  herpes simplex virus vaccine - Drug Profile1151
    Product Description1151
    Mechanism of Action1151
    R&D Progress1151
  HSV vaccine - Drug Profile1161
    Product Description1161
    Mechanism of Action1161
    R&D Progress1161
  HSV-529 - Drug Profile1171
    Product Description1171
    Mechanism of Action1171
    R&D Progress1172
  MB-66 - Drug Profile1191
    Product Description1191
    Mechanism of Action1191
    R&D Progress1191
  MBX-2168 - Drug Profile1201
    Product Description1201
    Mechanism of Action1201
    R&D Progress1201
  Monoclonal Antibody for Herpes Simplex Infections - Drug Profile1211
    Product Description1211
    Mechanism of Action1211
    R&D Progress1211
  Monoclonal Antibody for Herpes Simplex Infections - Drug Profile1221
    Product Description1221
    Mechanism of Action1221
    R&D Progress1221
  NAVI - Drug Profile1231
    Product Description1231
    Mechanism of Action1231
    R&D Progress1231
  Peptide for HIV and HSV Infections - Drug Profile1241
    Product Description1241
    Mechanism of Action1241
    R&D Progress1241
  pritelivir - Drug Profile1251
    Product Description1251
    Mechanism of Action1251
    R&D Progress1252
  RC-100b - Drug Profile1271
    Product Description1271
    Mechanism of Action1271
    R&D Progress1271
  RKP-00156 - Drug Profile1281
    Product Description1281
    Mechanism of Action1281
    R&D Progress1281
  RPI-78M - Drug Profile1291
    Product Description1291
    Mechanism of Action1291
    R&D Progress1292

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Herpes-Simplex-Virus-HSV-Infections-Pipeline-Review-H1-2016-2088-15909>
  
APA:
Global Markets Direct - Market Research. (2016). Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Herpes-Simplex-Virus-HSV-Infections-Pipeline-Review-H1-2016-2088-15909>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.